EVAX
Evaxion A/S
$3.64
+0.83%
$30.4M
No data for this timeframe.
Vol
Market Cap$30.4M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders5 funds
Inst. Value$492.4K
Inst. Activity1 buys / 0 sells
Reddit Sentiment40° Cool
SEC Reports10
Press Releases13
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. G7·CIK 0001828253·Prev Close $3.61
Recent Activity
Jun 12, 2026
SEC
Evaxion announced it received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platf
6-K — Impact 3/10
Jun 11, 2026
SEC
Evaxion announced new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, show
6-K — Impact 6/10
May 12, 2026
SEC
Evaxion announced it will present preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine, at the EHA 2026
6-K — Impact 3/10
Inst.
RHUMBLINE ADVISERS — DOUBLED
21,090 shares ($100.6K)
Inst.
UBS Group AG — NEAR_EXIT
1 shares ($4.00)
Jun 12, 2026
Press
Evaxion receives the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. While th
Impact 3/10
Jun 12, 2026
announcement
Evaxion receives Prix Galien UK Award for Best digital health solution
<p align="justify">COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a cl
Jun 11, 2026
Press
Evaxion announced new preclinical data for its off-the-shelf AML vaccine EVX-04, demonstrating complete expression in hu
Impact 4/10
Price Targets
$11.25
+209.1% upside
Strong Buy
Current $3.64
Low $9.00
Median $10.00
High $16.00
4 analysts
$9.00
$16.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 24, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 10, 2026 | Jones Trading | INITIATE | Buy |
| Mar 9, 2026 | Lake Street | MAINTAIN | Buy → Buy |
| Mar 9, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.01 | $-0.01 — $-0.01 | 99% YoY | 1 |
| Next Q | $-0.01 | $-0.01 — $-0.01 | -200% YoY | 1 |
| Current FY | $-0.04 ▼ -60.0% | $-0.04 — $-0.04 | -100% YoY | 1 |
| Next FY | $0.04 | $-0.03 — $0.11 | 200% YoY | 2 |
Latest Reports
NEUTRAL
6-K
3/10
Evaxion announced it received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platf
Jun 12, 2026
NEUTRAL
Press
3/10
Evaxion receives the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. While th
Jun 12, 2026
BULLISH
6-K
6/10
Evaxion announced new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, show
Jun 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Rathbones Group PLC | $170.1K | — |
| RENAISSANCE TECHNOLOGIES LLC | $145.9K | — |
| RHUMBLINE ADVISERS | $80.6K | DOUBLED |
| CITADEL ADVISORS LLC | $66.1K | — |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT | $29.8K | — |
Reddit Sentiment
40°
Cool
Bearish
Neutral
Bullish
5 institutional holders with $492.4K total value (132,380 shares) as of 2026-Q1. Top holders: Rathbones, RENAISSANCE, RHUMBLINE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Rathbones Group PLC | 45,723 | $170.1K | 34.5% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 39,225 | $145.9K | 29.6% | — |
| 3 | RHUMBLINE ADVISERS | 21,659 | $80.6K | 16.4% | DOUBLED +123.5% |
| 4 | CITADEL ADVISORS LLC | 17,773 | $66.1K | 13.4% | — |
| 5 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 8,000 | $29.8K | 6.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | DOUBLED | 9,435 | 21,090 | +123.5% | $100.6K | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 2,039 | 1 | -100.0% | $4.00 | 2025-Q3 |
| RHUMBLINE ADVISERS | DOUBLED | 2,208 | 9,435 | +327.3% | $23.1K | 2025-Q2 |
| UBS Group AG | TRIM | 6,517 | 2,039 | -68.7% | $5.0K | 2025-Q2 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
10 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 7 neutral. Avg impact: 4.0/10.
NEUTRAL
6-K
3/10
Evaxion announced it received the 2026 Prix Galien UK Award for Best digital health solution for its
Jun 12, 2026
BULLISH
6-K
6/10
Evaxion announced new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute my
Jun 11, 2026
NEUTRAL
6-K
3/10
Evaxion announced it will present preclinical data for EVX-04, an off-the-shelf therapeutic AML vacc
May 12, 2026
NEUTRAL
6-K
3/10
Evaxion reported Q1 2026 results with net loss widening to $3.6M from $1.6M due to lower financial i
May 7, 2026
NEUTRAL
PRESS-RELEASE
1/10
Evaxion issued a press release announcing that it will report Q1 2026 financial results and host a c
May 4, 2026
NEUTRAL
6-K
3/10
Evaxion A/S announced the promotion of Birgitte Rn from Chief Scientific Officer (CSO) to a dual rol
Apr 27, 2026
NEUTRAL
6-K
3/10
Evaxion A/S held its Annual General Meeting on April 16, 2026, where shareholders approved amendment
Apr 22, 2026
BULLISH
6-K
8/10
Evaxion A/S announced phase 2 trial data showing its AI-designed personalized cancer vaccine EVX-01
Apr 17, 2026
BULLISH
6-K
7/10
Evaxion A/S announced new preclinical data demonstrating the scalability of its AI-Immunology platfo
Apr 17, 2026
NEUTRAL
6-K
3/10
Evaxion A/S held its Annual General Meeting on April 16, 2026, approved the 2025 Annual Report, and
Apr 16, 2026
NEUTRAL
3/10
Evaxion receives the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunolog
Jun 12, 2026
NEUTRAL
4/10
Evaxion announced new preclinical data for its off-the-shelf AML vaccine EVX-04, demonstrating compl
Jun 11, 2026
NEUTRAL
4/10
Evaxion announced a poster presentation at the EHA 2026 Congress detailing preclinical data for EVX-
May 12, 2026
NEUTRAL
3/10
Evaxion promoted its Chief Scientific Officer, Birgitte Rønø, to also serve as Chief Operating Offic
Apr 27, 2026
BULLISH
7/10
Evaxion announced new Phase 2 data for its AI-designed personalized cancer vaccine EVX-01, showing 8
Apr 17, 2026
BULLISH
7/10
Evaxion announced new data from a collaboration with Duke University showing its AI-Immunology™ plat
Apr 17, 2026
NEUTRAL
2/10
Evaxion held its Annual General Meeting, approving the 2025 Annual Report and re-electing four board
Apr 16, 2026
BULLISH
7/10
Evaxion announced the successful completion of the one-year extension of its phase 2 trial for its p
Apr 7, 2026
NEUTRAL
2/10
Evaxion announced the convening of its Annual General Meeting on April 16, 2026, to be held at its h
Mar 19, 2026
NEUTRAL
4/10
Evaxion announced two abstracts accepted for presentation at the AACR Annual Meeting, featuring new
Mar 17, 2026
BULLISH
8/10
Evaxion reported strong 2025 financial and clinical progress, highlighted by a $7.5M upfront from MS
Mar 5, 2026
NEUTRAL
3/10
Evaxion delayed the filing and publication of its 2025 annual report due to technical issues with ex
Mar 5, 2026
NEUTRAL
3/10
Evaxion announced it will release its full-year 2025 financial results and provide a business update
Mar 2, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.25 mean target
+209.1% upside
Strong Buy (3.00)
$9.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $3.64 |
| Target Low | $9.00 |
| Target Mean | $11.25 |
| Target Median | $10.00 |
| Target High | $16.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.01 | $-0.01 | $-0.01 | 99.0% | +0.0% | — | $0.0B | -100.0% | 1 |
| Next Q 2026-09-30 |
$-0.01 | $-0.01 | $-0.01 | -200.0% | +0.0% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Current FY 2026-12-31 |
$-0.04 | $-0.04 | $-0.04 | -100.0% | -60.0% | — | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$0.04 | $-0.03 | $0.11 | 200.0% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.010 | |
| 7d ago | $0.000 | -0.010 |
| 30d ago | $-0.010 | |
| 60d ago | $0.000 | -0.010 |
| 90d ago | $0.000 | -0.010 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 10, 2026 | Jones Trading | INITIATE | — | Buy |
| Mar 9, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
40°
Cool
Bearish
Neutral
Bullish
1 mentions
0 bullish
1 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 19, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Evaxion biotech (EVAX)
▲ 1
💬 1
⚡ 0.5
Jun 12, 2026
announcement
Evaxion receives Prix Galien UK Award for Best digital health solution
<p align="justify">COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vacc
Jun 11, 2026
announcement
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
<p align="justify">COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vacc
May 12, 2026
announcement
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
<p align="justify">COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vacci
May 7, 2026
earnings
Evaxion announces business update and first quarter 2026 financial results
<p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccin
May 7, 2026
earnings_calendar
EVAX Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
earnings
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
<p align="justify">COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccin
Apr 27, 2026
announcement
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
<p align="justify">COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vac
Apr 17, 2026
announcement
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
<p align="justify">COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vac
Apr 17, 2026
announcement
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
<p align="justify">COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vac
Apr 16, 2026
announcement
Evaxion concludes Annual General Meeting
<p align="justify">COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vac
Apr 7, 2026
announcement
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
<p align="justify">COPENHAGEN, Denmark, April 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vacc
Mar 30, 2026
announcement
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
<p align="justify">COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vac
Mar 19, 2026
announcement
Notice to convene Evaxion’s Annual General Meeting
<p align="justify">COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vac
Mar 17, 2026
announcement
Evaxion to present new data at AACR Annual Meeting
<p align="justify">COPENHAGEN, Denmark, March 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vac
Mar 5, 2026
announcement
Evaxion announces business update and full year 2025 financial results
<p align="justify">COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vacc